一个强大的PARP1抑制剂Senaparib的发现
Sui X Cai1, Ning Ma1, Xiaozhu Wang1
1IMPACT Therapeutics Inc., Shanghai, China.
Molecular cancer therapeutics
|June 26, 2024
概括
塞纳帕里布是一种新型的多ADP-ribosyl化 (PARP) 抑制剂,有效向具有BRCA1/2突变的瘤. 这种强大的PARP1/2抑制剂在临床前模型和卵巢癌的成功III期临床试验中显示出有效性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 聚ADP-ribosyl) 化 (PARP) 酶,特别是PARP1,对于修复DNA损伤至关重要.
- PARP 抑制剂有效治疗具有同源重组缺陷的癌症,例如 BRCA1/2 突变的癌症.
- 已批准的PARP抑制剂针对PARP1和PARP2,利用酶抑制和DNA捕获机制.
研究的目的:
- 推出Senaparib,一种具有独特化学结构和高强度的新型PARP1抑制剂.
- 评估Senaparib在临床前癌症模型中的疗效,包括那些具有BRCA1/2突变的癌症模型.
- 为了评估Senaparib与temozolomide结合的协同效应.
主要方法:
- 实验室细胞活力测试针对具有BRCA1/2突变的瘤细胞.
- 使用细胞系衍生和患者衍生异种移植模型的体内疗效研究.
- 与temozolomide的组合研究,以评估协同性细胞毒性.
主要成果:
- 塞纳帕里布在抑制PARP1/2酶方面表现出高强度,并在针对BRCA1/2-突变瘤细胞的细胞活力测试中表现出高效.
- 塞纳帕里布在BRCA1/2-突变瘤的细胞系衍生和患者衍生异种移植模型中都显示出显著的疗效.
- 与Senaparib和temozolomide的联合治疗在体外和体内表现出强烈的协同性细胞毒性.
结论:
- 塞纳帕里布 (Senaparib) 是一种新型类型的强效PARP1抑制剂,在癌症治疗中具有显著的治疗潜力.
- 塞纳帕里布已经显示出有前途的临床结果,在III期卵巢癌试验中达到其主要终点.
- 塞纳帕里布的开发正在推进,在中国接受了一项新的药物申请进行审查.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K